VTRS - Viatris Stock: Way Too Undervalued With $1 Billion Buyback Potential

2024-04-08 17:01:16 ET

Summary

• Viatris Inc. is a deep value pharmaceutical company with a low valuation and a 4.1% yield.
• Viatris has seen a slowdown in top line decline and has a promising pipeline of potential blockbuster drugs.
• Management is de-risking the balance sheet and returning capital to shareholders through dividends and share repurchases.

There is quite a pronounced valuation gap in the pharmaceuticals sector, with richly priced names like Eli Lilly and Company ( LLY ) and Novo Nordisk A/S ( NVO ) on the high-end of the spectrum, and others like Bristol Myers Squibb Company ( BMY ) and Gilead Sciences, Inc. ( GILD ) on the other end....

For further details see: